newsfilter
← Latest News
Business Wire·

Innovation and Product Launch Momentum Drive Alcon’s Third-Quarter 2026 Growth

ALC
  • Alcon reported third-quarter 2026 sales of $2.7 billion, a 5% increase vs. Q3 2025, with year-to-date sales of $8.2 billion, up 7%.
  • Diluted EPS for Q3 2026 was $0.54 (up 13%), while core diluted EPS was $0.91 (up 15%).
  • Year-to-date diluted EPS was $0.92, down 40% due to a $287 million non-cash charge related to PowerVision program discontinuation, whereas core diluted EPS rose 14% to $2.60.
  • The company returned $748 million to shareholders year-to-date through dividends and share repurchases, with $210 million returned in Q3 alone.
  • Alcon recently announced the acquisition of Neurotech Pharmaceuticals to strengthen its retinal disease portfolio with ENCELTO, the first FDA-approved treatment for MacTel Type 2.
  • Surgical segment sales reached $1.5 billion in Q3 (up 4%), driven by consumables & equipment, though implantables sales declined 2% due to U.S. competitive pressures.
  • Vision Care segment sales totaled $1.2 billion in Q3 (up 6%), led by growth in ocular health products like dry eye solutions.
  • Operating margin for Q3 2026 was 14.0%, while core operating margin increased to 21.8%.
  • The 2026 outlook was tightened to net sales growth of ~6%, core operating margin growth of 100-150 basis points, and core diluted EPS growth of 12-14%.
  • Efficiency measures expanded in November 2026 now carry estimated total costs of $230 million with run-rate savings projected at $130 million.
  • Alcon received two 2026 Prix Galien USA nominations for its UNITY VCS system & TRYPTYR product.
  • The FDA approved BRYTLY Redness Reliever Eye Drops in October to expand the consumer eye care portfolio.
  • Net cash flows from operating activities were $1.7 billion for the first nine months of 2026, with free cash flow at $1.3 billion.